Boehringer Ingelheim Press Releases

Boehringer Ingelheim further strengthens animal health presence in China: Manufacturing joint venture for veterinary vaccines

Jentadueto™ (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe

€100,000 in reward donations for projects fundraising to prevent atrial fibrillation-related strokes

One million signatures needed to call upon World Health Organisation to save lives through education and improved management of atrial fibrillation

Boehringer Ingelheim announces positive phase II results for once-daily tiotropium in asthma

Boehringer Ingelheim’s once-daily bronchodilator olodaterol* successfully completes Phase II clinical trial program in COPD

Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals

Boehringer Ingelheim on growth path - Successful 2011 financial year

GLORIA^TM-AF Registry Program investigating use of antithrombotic therapy in 56,000 patients with atrial fibrillation at risk of stroke announced

Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*)

First ever data investigating interferon-free treatment in hepatitis C patients who have liver cirrhosis shows high viral cure rate

Leading medical and patient organisations join forces to improve stroke prevention in atrial fibrillation

Dabigatran etexilate (Pradaxa®) associated with significantly lower rates of fatal and traumatic intracranial haemorrhage compared with Warfarin

Pradaxa® (dabigatran etexilate) – first new oral anticoagulant in nearly 60 years receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK¹

Boehringer Ingelheim sets up its first Asian Veterinary Research & Development Center in Shanghai

Porcine circovirus research projects from France and Spain awarded

Boehringer Ingelheim expands capabilities in biopharmaceutical process science

Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies